Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acute Coronary Syndrome
- Sponsor
- AstraZeneca
- Enrollment
- 4992
- Locations
- 1
- Primary Endpoint
- Medical information
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
Detailed Description
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
- •No Exclusion Criteria.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Medical information
Time Frame: At baseline visit
History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
Drug exposure
Time Frame: Past
Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Secondary Outcomes
- Other medical events of interest(During follow-up (up to 12 months))